Aims: Contemporary data describing type 2 diabetes prevalence, incidence and mortality are limited. We aimed to (1) estimate annual incidence and prevalence rates of type 2 diabetes in the UK between 2004 and 2014, (2) examine relationships between observed rates with age, gender, socio-economic status and geographic region, and (3) assess how temporal changes in incidence and all-cause mortality rates influence changes in prevalence. Conclusions: The rising prevalence of type 2 diabetes in the UK over the last decade is probably explained by patients living longer rather than by increasing incidence of type 2 diabetes.
| INTRODUCTION
The prevalence of diabetes is increasing rapidly worldwide. [1] [2] [3] [4] In 2016, the World Health Organization (WHO) reported that nearly 422 million adults live with diabetes; this is an increase in global prevalence from 4.7% in 1980 to 8.5% in 2014. 5 Similarly, in the UK, diabetes is described as the fastest growing health condition 6 where prevalence has almost doubled over the last 2 decades. 7, 8 However, studies in the UK were often based on restricted local areas within the country, 9-11 estimated either incidence 12 or prevalence 10 of type 2 diabetes mellitus (T2DM), but not both simultaneously, or they examined trends over a short study period. 11 A recent study examined UK trends in T2DM incidence and prevalence from 2000 to 2013 but it did not consider regional variation or the potential influence of changing mortality rates. 8 Using UK-based primary care data, we aimed to (1) assess temporal trends in incidence and prevalence rates of T2DM stratified by gender, age and social-deprivation between 2004 and 2014, (2) assess the contribution of incidence and mortality rates to observed prevalence, and (3) compare differences in all-cause mortality between patients with T2DM and those without diabetes.
2 | METHODS
| Data source
The Clinical Practice Research Datalink (CPRD) is an electronic database based on primary care health records in the UK. 13, 14 The CPRD provides longitudinal anonymized data on patient demographics, clinical diagnoses, prescribed treatments, tests, referrals and linkage to external datasets and disease registries. Currently, CPRD holds research-quality data on nearly 14 million patients registered with 697 general practices. Practice-level socio-economic data, as indicated by the index of multiple deprivation (IMD), is available. The IMD is a composite score constructed from the following domains of deprivation: finance, education, health, access to services and crime. 15 The
Quality and Outcomes Framework (QOF) scheme was introduced in 2004 as an incentive to UK general practices providing high-quality care including diabetes management. 16 The study period was initiated at the QOF launch to maximize the quality of captured data.
| Patient population 2.2.1 | Examining incidence and prevalence
Patients aged ≥16 years with ≥1 diagnostic Read code for T2DM between January 2004 and December 2014, with data of an acceptable quality, were included. Patients with codes for type 1 diabetes were excluded.
| Examining all-cause mortality
Patients with ≥1 diagnostic code for T2DM, who were registered for ≥90 days in an up-to-standard general practice and were ≥16 years of age at diagnosis between 2004 and 2014 were identified. We excluded patients with any clinical code for type 1 diabetes. The up-to-standard criterion indicates that practice data are of high quality for use in research, based on the continuity of data recording and mortality rate compared with the expected range. 13, 14 Up to 5 patients without diabetes were matched to each T2DM patient on age (birth year difference of ≤2 years), gender and the general practice they are registered with.
Eligible patients were followed up from their index date, the earliest date of T2DM diagnosis, until the earliest date among the following events: date of last data collection for the practice; patient transfer out of the practice; end of study (December 31, 2014) or death. Comparators without diabetes were assigned the corresponding index date of the diabetes case and followed up in the same manner.
| Statistical analyses 2.3.1 | Incidence and prevalence rates
Overall and annual crude incidence rates of T2DM were calculated by dividing the number of new cases diagnosed in a given year by the total population at risk. Calculated incidence rates were expressed per 10 000 person-years (PYR) at risk with 95% confidence intervals (95% CI). Overall and annual standardized incidence rates were calculated by age at diagnosis, UK country, or deprivation quintiles by adjusting for the respective factors. For instance, for estimation of gender-specific incidence rates by UK country, rates were standardized by age and deprivation quintiles.
Overall and annual crude prevalence rates were calculated as percentage (95% CI) and per 10 000 PYR at risk (95% CI). Rates were calculated as the number of existing T2DM patients in a given year (without restriction regarding past record of T2DM) divided by the total number of registered patients for that year. As with incidence rates, standardized prevalence rates were adjusted for age, UK country or deprivation quintile, depending on the stratification of interest.
To assess if results will differ from annual rates, incidence and prevalence rates were calculated also over a fixed number of years using two sets of intervals: (1) Figure S1 ). Over the 11-year period, the mean incidence per 10 000 were also estimated in the 3 age-groups ( Figure S2 ).
| Prevalence of type 2 diabetes
The prevalence of T2DM increased steadily over time. Table 2) . Among diabetes patients, 44% were receiving lipid-regulating medications and 52% had hypertension as compared to 4% and 30%, respectively, in controls.
In the survival analysis, the cohort of matched diabetes cases and controls was followed for a total of 4555 266 person-years (mean AE Table S3 ).
Annual gender-specific mortality rates were calculated ( Figure S5 ).
When assessed by the durration of follow-up, the excess risk asso- 1.34) with proportional hazards (P = .27).
4 | DISCUSSION
| Main findings
We have shown that T2DM prevalence rates rose by two-thirds while incidence rates were generally stable in the UK for the period 2004 to 2014. Ageing population is the likely explanation for the observed increase in prevalence. Incidence and prevalence rates were markedly higher in men than in women and this trend persisted throughout the study period after adjusting for age, UK country and We found that all-cause mortality rates declined over the study period in all patients. Significantly higher mortality rates were observed in patient with T2DM compared to patients without diabetes. This finding builds up to previous reports that diagnosis with diabetes is associated with greater risk of mortality when compared to the general population. 
| Prior studies
The reported findings add to the existing knowledge, as the majority of previous studies examined the epidemiology of combined type 1 and T2DM, 7,21 estimated incidence 12 or prevalence of T2DM, 10 and not both simultaneously, covered a short study period, 11 or were based on restricted local areas within the UK, which limits the generalizability of the findings for nationwide representation. 9-11 Moreover, few studies have assessed the association between incidence, prevalence and mortality in patients with T2DM.
For example, a Dutch study estimated these rates in T2DM
between 1998 and 2000. 3 However, the study was smaller than the present study (N = 4423) and mortality rates were compared to the 21 This study examined all types of diabetes, and mortality rates were not adjusted for socio-economic data. In comparison, our UK incidence was lower (4.5 per 1000 patients in 2004).
The higher prevalence of diabetes in Canada compared to the UK has been reported previously. 22 In a separate report, temporal trends in mortality rates in indviduals with and without diabetes in Canada and the UK were compared. 17 4 In contrast, women are more likely to have T2DM in the Netherlands. 3 Concerning age, our finding that the incidence of T2DM at a young age has increased over the past decade builds upon a previous study that assessed early incidence in patients aged <40 years during the period 1991 to 2010. 12 We showed decreasing mortality rates, which is in agreement with UK national reports, in individuals with and without diabetes between 1983 and 2013 24 and in Scotland between 1993 and 2004. 9 Our findings also showed a 26% higher risk of mortality in T2DM patients compared to those without diabetes, confirming the mortality gap highlighted in many guidelines and reports on the association between diabetes and premature death. 18, 25 However, the observed excess risk was slightly lower than that from other reports. 17, 18 This difference may be explained by improvements in care in the T2DM population over recent years (e.g. in cardiovascular disease management) and to the similar durations of follow-up between cases and matched controls. The latter (similar follow-up durations) was also observed in a recent report. 19 In our study, the similar duration of follow-up was driven mainly by the practicedetermined censor point (last date for contribution of data) which was the main censor point in the identified matched cohort.
This excess risk of mortality in diabetes patients was comparable to more recent studies. 19, 26 For example, a large study from Sweden, Mortlaity rate per 10,000 PYRs T2DM Controls FIGURE 3 Crude annual mortality rates per 10 000 person-years (PYRs) (95% CI) for type 2 diabetes (T2DM) cases and matched patients without diabetes (controls) during follow-up followed up matched T2DM cases for 4.6 years and controls for 4.8 years and showed that the adjusted HR for all-cause mortality associated with diabetes was 1.15 (1.14; 1.16) between 1998 and 2011. 19 The investigators attributed this comparatively low excess risk to improved medical care over time. In keeping with this idea, we
showed that antihypertensive and lipid-lowering therapies were prescribed for up to 28% and 44%, respectively, of patients with type 2 diabetes. Similar to our CPRD results, the latest National Diabetes Audit (NDA) data on complications and mortality (2012-2013) 27 reported: (1) a 32% excess risk for mortality in T2DM patients than in the general population; (2) that excess risk was higher in women; (3) that excess risk for mortality in patients with T2DM declined between the 2009 to 2010 and 2011 to 2012 audits, recommending that further studies are needed to examine the future patterns of this reduced trend.
| Worldwide perspective on type 2 diabetes incidence and prevalence
The observed incidence plateau in our study was seen previously in 2 relevant UK studies. Firstly, our overall stable incidence is comparable to the trend observed between 2004 and 2012 in a similar primary care database (THIN). 8 Secondly, the incidence rates of T2DM Importantly, a recent study assessed whether the quality of recording of diabetes in the UK has affected the reported incidence and prevalence estimates of diabetes between 1995 and 2014. 28 The conclusion, in contrast to previous reports, was that the incidence of diabetes, based on diagnostic codes, has not increased in the UK since 2004, suggesting that the choice of codes has a significant effect on incidence estimates. This important finding agrees with the approach adopted in our case definition strategy (excluding type 1 diabetes cases) which aimed to minimize misclassification of T2DM.
International diabetes organizations have reported on the increasing prevalence rates of diabetes, but not necessarily on incidence rates in all regions. 22, 29 The number of people with diabetes is increasing in the UK and worldwide. [1] [2] [3] [4] Our findings showed a rapidly increasing prevalence of T2DM in the UK over the last decade, which builds on the findings of relevant observational studies and national reports. 
| Strengths and limitations
Our study has several strengths. This is the first large study to provide insight into the inter-relationship between prevalence, incidence and mortality rates in T2DM patients across the UK. Secondly, the study had a large sample size, representative of the UK population and drawing on nearly 14 million CPRD patients. Thirdly, the study included patients from the 4 UK countries, increasing the external validity of our findings. Fourthly, the selected study period was relevant to the current clinical practice scheme, ranging from QOF introduction to 2014. Fifthly, our incidence and prevalence rates were adjusted for several factors including country within the UK; this enabled an assessment of country-specific temporal rates which may reflect on the effectiveness of local diabetes prevention and management strategies.
We acknowledge some limitations in our study. Firstly, our T2DM cohort was based on diagnosed cases in the primary care database and represents consulting prevalence rates for T2DM. However, overall prevalence rates were similar to annual national estimations. 25, 30 Secondly, although the all-cause mortality analysis took into account several important covariates, the possibility of residual confounding cannot be excluded.
| Conclusions
We have shown that T2DM prevalence rates rose by two-thirds while incidence rates were generally stable in the UK for the period 2004 to 2014. Improvements in life expectancy were observed during the study period, which is probably the key driver of the observed increase in prevalence. Higher incidence and prevalence rates were observed in older males from more socially deprived areas. The incidence of T2DM at a young age increased over the past decade.
Patients with T2DM were at significantly higher risk of all-cause mortality than were patients without diabetes. These data support ongoing efforts to improve the prevention and effective management of T2DM through social and medical intervention. 
